Last reviewed · How we verify
JW0104+C2403
JW0104+C2403 is a Small molecule drug developed by JW Pharmaceutical. It is currently in Phase 3 development for Oncology indication (specific indication not publicly disclosed). Also known as: NA (Not Applicable).
JW0104+C2403 is a combination therapy designed to enhance anti-tumor immunity through dual mechanism targeting.
JW0104+C2403 is being studied in a clinical trial for its efficacy and safety in treating patients with hypertension and dyslipidemia. The trial is a multi-center, randomized, double-blind, parallel, Phase Ⅲ clinical trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | JW0104+C2403 |
|---|---|
| Also known as | NA (Not Applicable) |
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a combination of JW0104 (an investigational immunotherapeutic) and C2403 (an investigational agent from JW Pharmaceutical). The exact molecular mechanisms are not publicly detailed, but the combination approach in phase 3 suggests synergistic immunomodulatory or checkpoint-related activity. Specific target details remain proprietary.
Approved indications
- Oncology indication (specific indication not publicly disclosed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JW0104+C2403 CI brief — competitive landscape report
- JW0104+C2403 updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI
Frequently asked questions about JW0104+C2403
What is JW0104+C2403?
How does JW0104+C2403 work?
What is JW0104+C2403 used for?
Who makes JW0104+C2403?
Is JW0104+C2403 also known as anything else?
What development phase is JW0104+C2403 in?
Related
- Manufacturer: JW Pharmaceutical — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Oncology indication (specific indication not publicly disclosed)
- Also known as: NA (Not Applicable)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing